We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.50 | -0.09% | 1,727.00 | 1,726.50 | 1,727.50 | 1,739.50 | 1,724.50 | 1,733.00 | 2,304,054 | 15:47:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.47 | 71.33B |
Date | Subject | Author | Discuss |
---|---|---|---|
02/11/2018 12:59 | I got chart support 1430p & resistance 1540p, so in no mans land here | ny boy | |
02/11/2018 09:27 | Still happy to wait and see if I get lucky from Mr Market around 1475/1485p area | ny boy | |
01/11/2018 10:15 | Swing time | tradermichael | |
01/11/2018 09:47 | I think you'll find that it has been 80p for 4 years Monty, not 10! Prior to that (2004 - 2014) the divi grew impressively from 40p to 80p. I think we investors deserve a small divi rise next year, but I will continue to hold whatever. N.R. | nik rosa | |
01/11/2018 09:46 | For the last two days it looks GSK is following in the footsteps of Vodafone,people love them equally. | abdullla | |
01/11/2018 09:11 | Cannot agree with that! | tradermichael | |
01/11/2018 08:27 | Same dividend for about 10 years where is the growth coming from. It's more like a bond, but with more risk. | montyhedge | |
31/10/2018 19:26 | GlaxoSmithKline's Shingrix zooms toward blockbuster status despite tight supply | philanderer | |
31/10/2018 17:50 | Market report.. Charlie Huggins, manager of the Hargreaves Lansdown Select UK Income Shares fund which holds shares in Glaxo, commented: "We are encouraged by this performance, however we aren't going to get too excited by one quarter. Confidence in GSK's drug pipeline is still fairly thin on the ground, especially relative to its UK peer, AstraZeneca, which has recently enjoyed a flurry of new drug approvals." | philanderer | |
31/10/2018 15:57 | I will try to add sub 1500p tomorrow, looking for around 1475p/1485p, see how this plays out tomorrow, new month! | ny boy | |
31/10/2018 15:44 | Earnings slides for those interested... GlaxoSmithKline 2018 Q3 - Results - Earnings Call Slides | fangorn2 | |
31/10/2018 15:16 | It seems to be about expectations, that sometimes run ahead, which it often is with GSK. Remain long. | alphorn | |
31/10/2018 15:13 | The FTSE 100 drugmaker now expects full-year adjusted earnings per share to climb by 8-10% in 2018, while it is also guiding for overall full-year performance at the upper end of previous expectations | zho | |
31/10/2018 14:40 | it's +370 pts | philanderer | |
31/10/2018 14:13 | DOW tanking big time??? | abdullla | |
31/10/2018 14:13 | Flip flop still, lacks clear direction but ex Divi coming up soon, offers crumbs, decent numbers, will read the write ups later/tomorrow. | ny boy | |
31/10/2018 14:06 | ric - as excellent as it was, I think the performance at Q3 was expected by the market. There should be another run up to xd, though ……. ;0) | tradermichael | |
31/10/2018 14:05 | Now 50p down on intraday highs. | abdullla | |
31/10/2018 14:01 | Following the Vodafone line. | abdullla | |
31/10/2018 13:59 | Good results and yet share price easing back. could end up down on the day? | ric0chet | |
31/10/2018 13:57 | SP not holding water. | abdullla | |
31/10/2018 12:19 | Here she blows! | abdullla |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions